Literature DB >> 8425711

New strategies needed for treatment of primary biliary cirrhosis?

M M Kaplan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8425711     DOI： 10.1016/0016-5085(93)90440-n

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  5 in total

1.  Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis.

Authors:  K E Kisand; A L Karvonen; M Vuoristo; M Färkkilä; J Lehtola; J Inkovaara; K V Kisand; T Miettinen; K Krohn; R Uibo
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

2.  A modest proposal for future trials of medical treatment in inflammatory bowel disease.

Authors:  H D Janowitz
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

3.  Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis.

Authors:  T H Mauad; C M van Nieuwkerk; K P Dingemans; J J Smit; A H Schinkel; R G Notenboom; M A van den Bergh Weerman; R P Verkruisen; A K Groen; R P Oude Elferink
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

Review 4.  Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.

Authors:  Francesca Saffioti; Kurinchi Selvan Gurusamy; Leonardo Henry Eusebi; Emmanuel Tsochatzis; Brian R Davidson; Douglas Thorburn
Journal:  Cochrane Database Syst Rev       Date:  2017-03-28

5.  Synthesis and Biological Evaluation of Novel Triple-Modified Colchicine Derivatives as Potent Tubulin-Targeting Anticancer Agents.

Authors:  Urszula Majcher; Greta Klejborowska; Magdalena Kaik; Ewa Maj; Joanna Wietrzyk; Mahshad Moshari; Jordane Preto; Jack A Tuszynski; Adam Huczyński
Journal:  Cells       Date:  2018-11-19       Impact factor: 6.600
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.